Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Updated daily

Drug recalls

Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.

Class IITerminatedSep 23, 2015MYO-DEN InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1715-2015Class IITerminatedSep 23, 2015Myers Cocktail InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1714-2015Class IITerminatedSep 23, 2015Morphine 60 mg/ml + Fentanyl 12Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1713-2015Class IITerminatedSep 23, 2015Morphine 50 mg/ml + Fentanyl 20Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1712-2015Class IITerminatedSep 23, 2015Morphine 50 mg/ml + Ropivacaine 5 mg/ml +Baclofen 20 mcg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1711-2015Class IITerminatedSep 23, 2015Morphine 50 mg/ml + Fentanyl 3Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1710-2015Class IITerminatedSep 23, 2015Morphine 50 mg/ml + Fentanyl 3Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1709-2015Class IITerminatedSep 23, 2015Morphine 50 mg/ml + Fentanyl 2Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1708-2015Class IITerminatedSep 23, 2015Morphine 50 mg/ml + Fentanyl 10Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1707-2015Class IITerminatedSep 23, 2015Morphine 50 mg/ml + Fentanyl 1Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1706-2015Class IITerminatedSep 23, 2015Morphine 50 mg/ml + Clonidine 750 mcg/ml + Baclofen 15 mcg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1705-2015Class IITerminatedSep 23, 2015Morphine 50 mg/ml + Clonidine 500 mcg/ml +Bupivacaine 2.5 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1704-2015Class IITerminatedSep 23, 2015Morphine 45 mg/ml + Bupivacaine 8 mg/ml + Baclofen 25 mcg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1703-2015Class IITerminatedSep 23, 2015Morphine 25 mg/ml + Bupivacaine 30 mg/ml + Clonidine 200 mcg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1702-2015Class IITerminatedSep 23, 2015Morphine 25 mg/ml + Bupivacaine 20 mg/ml + Clonidine 2Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1701-2015Class IITerminatedSep 23, 2015MEGA-BURN* InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1700-2015Class IITerminatedSep 23, 2015MEGA-BURN III InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1699-2015Class IITerminatedSep 23, 2015MEGA-BURN IV InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1698-2015Class IITerminatedSep 23, 2015MEGA-BURN Injectable ROCK CREEKLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1697-2015Class IITerminatedSep 23, 2015MEGA-BURN InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1696-2015Class IITerminatedSep 23, 2015Lipovicine-Choline 100 mg/ml-Acorbic Acid 45 mg/ml InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1695-2015Class IITerminatedSep 23, 2015Lipovicine Modified II InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1694-2015Class IITerminatedSep 23, 2015Lipotropic Methyl B-12 InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1693-2015Class IITerminatedSep 23, 2015Lipotropic B-12 II* + Lidocaine InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1692-2015Class IITerminatedSep 23, 2015Lipotropic B-12 InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1691-2015Class IITerminatedSep 23, 2015LipotropicLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1690-2015Class IITerminatedSep 23, 2015LIPO-VITE IIILack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1689-2015Class IITerminatedSep 23, 2015LIPO-VITE InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1688-2015Class IITerminatedSep 23, 2015LIPO-Tropic InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1687-2015Class IITerminatedSep 23, 2015LIPO-EXTREME InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1686-2015Class IITerminatedSep 23, 2015LIPO-DEN MODIFIED InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1685-2015Class IITerminatedSep 23, 2015Lipo-DEN III InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1684-2015Class IITerminatedSep 23, 2015Lipo-B MMC ILack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1683-2015Class IITerminatedSep 23, 2015Hydromorphone 80 mg/ml + Bupivacaine 10 mg/ml + Clonidine 1Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1682-2015Class IITerminatedSep 23, 2015Hydromorphone 70 mg/ml +Fentanyl 16Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1681-2015Class IITerminatedSep 23, 2015Hydromorphone 70 mg/ml + Bupivacaine 20 mg/ml + Clonidine 125 mcg/ml Intrathecal SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1680-2015Class IITerminatedSep 23, 2015Hydromorphone 60 mg/ml + Fentanyl 7Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1679-2015Class IITerminatedSep 23, 2015Hydromorphone 60 mg/ml + Fentanyl 15Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1678-2015Class IITerminatedSep 23, 2015Hydromorphone 60 mg/ml + Fentanyl 20Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1677-2015Class IITerminatedSep 23, 2015Hydromorphone 60 mg/ml + Fentanyl 1Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1676-2015

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.